RANDOMISED DOUBLE-BLIND PHASE III TRIAL OF CEDIRANIB (AZD 2171) IN RELAPSED PLATINUM SENSITIVE OVARIAN CANCER: RESULTS OF THE ICON6 TRIAL.

被引：0
|
作者：
Raja, F. A. [1 ,2 ]
Perren, T. J. [3 ]
Embleton, A. [4 ]
Rustin, G. J. S. [5 ]
Jayson, G. [6 ]
Swart, A. M. [4 ]
Vaughan, M. [7 ]
Hirte, H. [8 ]
Stark, D. P. [9 ]
Ledermann, J. A. [1 ,2 ]
机构：
[1] Canc Res UK, London, England
[2] UCL Canc Inst, UCL Canc Trials Ctr, London, England
[3] St James Univ Hosp, Dept Oncol, Leeds LS9 7TF, W Yorkshire, England
[4] MRC, Clin Trials Unit, London, England
[5] Mt Vernon Hosp, Dept Oncol, Northwood HA6 2RN, Middx, England
[6] Christie Hosp, Dept Oncol, Manchester, Lancs, England
[7] Christchurch Hosp, Christchurch, New Zealand
[8] Hamilton Reg Canc Ctr, Hamilton, ON L8V 1C3, Canada
[9] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2013年 / 23卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of meloxicam in the treatment of rheumatoid arthritis (RA): Results of a phase III double-blind, placebo controlled trial.
    Furst, DE
    Hall, DB
    Roszko, PJ
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S225 - S225
  • [22] Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
    Lheureux, Stephanie
    Cristea, Mihaela C.
    Bruce, Jeffrey P.
    Garg, Swati
    Cabanero, Michael
    Mantia-Smaldone, Gina
    Olawaiye, Alexander B.
    Ellard, Susan L.
    Weberpals, Johanne I.
    Hendrickson, Andrea E. Wahner
    Fleming, Gini F.
    Welch, Stephen
    Dhani, Neesha C.
    Stockley, Tracy
    Rath, Prisni
    Karakasis, Katherine
    Jones, Gemma N.
    Jenkins, Suzanne
    Rodriguez-Canales, Jaime
    Tracy, Michael
    Tan, Qian
    Bowering, Valerie
    Udagani, Smitha
    Wang, Lisa
    Kunos, Charles A.
    Chen, Eric
    Pugh, Trevor J.
    Oza, Amit M.
    LANCET, 2021, 397 (10271): : 281 - 292
  • [23] CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
    Fennell, Dean A.
    Kirkpatrick, Emma
    Cozens, Kelly
    Nye, Mavis
    Lester, Jason
    Hanna, Gerard
    Steele, Nicola
    Szlosarek, Peter
    Danson, Sarah
    Lord, Joanne
    Ottensmeier, Christian
    Barnes, Daniel
    Hill, Stephanie
    Kalevras, Mihalis
    Maishman, Tom
    Griffiths, Gareth
    TRIALS, 2018, 19
  • [24] Radiotherapy for Ledderhose disease: a randomised, double-blind, phase III trial (NCT03507010)
    de Haan, A.
    van Nes, J. G.
    van der Toorn, P.
    Westenberg, A. H.
    Kolff, M. W.
    van der Laan, H. P.
    Werker, P. M.
    Langendijk, J. A.
    Steenbakkers, R. J.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S752 - S752
  • [25] A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).
    Matulonis, Ursula
    Mahner, Sven
    Wenham, Robert Michael
    Ledermann, Jonathan A.
    Monk, Bradley J.
    Campo, Jose Maria Dei
    Berek, Jonathan S.
    Vergote, Ignace
    Fabbro, Michel
    Katsaros, Dionyssios
    Marth, Christian
    Lorusso, Domenica
    Herrstadt, Jorn
    Agarwal, Shefali
    Martell, Robert E.
    Mirza, Mansoor Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] A phase 2 trial exploring the significance fi cance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
    Liu, Joyce F.
    Xiong, Niya
    Wenham, Robert M.
    Wahner-Hendrickson, Andrea
    Armstrong, Deborah K.
    Chan, Nancy
    O'Malley, David M.
    Lee, Jung-Min
    Penson, Richard T.
    Cristea, Mihaela C.
    Abbruzzese, James L.
    Matsuo, Koji
    Olawaiye, Alexander B.
    Barry, William T.
    Cheng, Su-Chun
    Polak, Madeline
    Swisher, Elizabeth M.
    Shapiro, Geoffrey I.
    Kohn, Elise C.
    Ivy, S. Percy
    Matulonis, Ursula A.
    GYNECOLOGIC ONCOLOGY, 2024, 187 : 105 - 112
  • [27] Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial
    Binghe Xu
    Zefei Jiang
    Zhimin Shao
    Jiayu Wang
    Jifeng Feng
    Shuping Song
    Zhendong Chen
    Kangsheng Gu
    Shiying Yu
    Yiping Zhang
    Chuan Wang
    Fengchun Zhang
    Junlan Yang
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 223 - 230
  • [28] Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial
    Xu, Binghe
    Jiang, Zefei
    Shao, Zhimin
    Wang, Jiayu
    Feng, Jifeng
    Song, Shuping
    Chen, Zhendong
    Gu, Kangsheng
    Yu, Shiying
    Zhang, Yiping
    Wang, Chuan
    Zhang, Fengchun
    Yang, Junlan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 223 - 230
  • [29] ICON7: FINAL OVERALL SURVIVAL RESULTS IN THE GCIG PHASE III RANDOMISED TRIAL OF BEVACIZUMAB IN NEWLY DIAGNOSED OVARIAN CANCER
    Pujade-Lauraine, E.
    Oza, A. M.
    Perren, T. J.
    Swart, A. M.
    Mahner, S.
    Gourley, C.
    Malander, S.
    Plante, M.
    Beale, P.
    Poveda, A.
    Kaplan, R.
    Embleton, A. C.
    Parmar, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [30] Safety Assessment of Niraparib Individualized Starting Dose in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: The Randomized, Double-Blind, Placebo-Controlled, Phase III NORA Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 13 - 14
12345